Novo Nordisk A/S (NONOF)
PNK · Drug Manufacturers - General
Sources: Yahoo Finance (quote, statistics) · SEC EDGAR (filings, insider trades, 13F holders) · company filings & press wires
Company overview
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products. It operates through two segments, Obesity and Diabetes Care, and Rare Disease. The Obesity and Diabetes care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides NovoPen 6 and NovoPen Echo Plus, smart insulin pens; Dose Check, an insulin dose guidance application; growth hormone pens and injection needles; and Wegovy pill an oral glucagon-like peptide-1 (GLP-1) receptor agonist therapy for weight management. It operates in Europe, Canada, the United States, Japan, Korea, Oceania, Southeast Asia, Mainland China, Hong Kong and Taiwan, Latin America, the Middle East, and Africa. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Peers in Healthcare
Novo Nordisk A/S has no peer companies in this window.
Recent press releases
April 2026
Novo Nordisk's etavopivat significantly reduces SCD crises in Phase 3 data
# 📄 What This Document Is ✨ This document is a Form 6-K, which is a report filed with the U.S. Securities and Exchange Commission (SEC) by a foreign private issuer (Novo Nordisk). 📄 Think of this as a major public announcement that provides critical updates to investors about a key drug candidate.
Novo Nordisk repurchases stock, confirming DKK 3.1 billion spent
# 📰 What This Document Is 📜 This filing is a Form 6-K, which is a report used by foreign private issuers—companies that list shares in the U.S. but are headquartered elsewhere—to provide updates on material events. Since Novo Nordisk is a Danish company, the 6-K acts like a formal announcement to
NOVO NORDISK A S — 6-K Filing
# 📄 What This Document Is This is a **Form 6-K** filing with the U.S. Securities and Exchange Commission (SEC). It's a routine report from a foreign company (Novo Nordisk, based in Denmark) to update American investors on a specific, important action: the progress of its share buyback program. 👉
March 2026
NOVO NORDISK A S — 6-K Filing
# 🧾 What This Document Is This is a **Form 6-K**, a standard report that foreign companies like Novo Nordisk file with the U.S. SEC to keep American investors informed. This specific report is a routine update on their ongoing share buyback program. 👉 In simple terms: It’s a public receipt showin
SEC filings
All filings →Insider trades
All insider trades →Novo Nordisk A/S has no reported insider trades in the last 90 days.
Institutional holders
All holders →People at Novo Nordisk A/S
All people →No officers or directors have been indexed for Novo Nordisk A/S.